- Findings Presented at the American College of Cardiology 57th Annual
Scientific Session -
FREMONT, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, presented data from a study providing further confirmation that the Company's multi-protein biomarker panel may aid in the diagnosis of peripheral artery disease (PAD). The research suggests that such a panel may be useful in alerting physicians to the possibility of PAD in patients who might otherwise be undiagnosed. Results of the study were presented as a poster at the American College of Cardiology 57th Annual Scientific Session.
Working in collaboration with researchers at Stanford University, Vermillion intends to develop a blood test for the diagnosis of PAD. In March, the Company entered into an exclusive license agreement with the University to develop and commercialize a biomarker panel used to assess the risk of the disease, which is estimated to affect up to 12 million Americans and can result in severe complications, including amputation, heart attack, stroke and even death.
"Few studies have explored combinations of protein markers to create a distinct biomarker panel score to stratify individuals according to their risk of having PAD. However, our study successfully accomplishes this by discovering a multi-marker panel that could significantly aid in identifying such patients," said Eric T. Fung, M.D., Ph.D., Chief Scientific Officer of Vermillion. "We are pleased with these findings and are developing a clinical trial protocol to generate data for support of a submission to the U.S. Food and Drug Administration (FDA)."
The study was conducted to develop an
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved